首页 正文

International journal of molecular sciences. 2021 Dec 2;22(23):13071. doi: 10.3390/ijms222313071 Q14.92025

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells

评估乐伐替尼对索拉非尼抗性肝癌细胞的影响 翻译改进

Tingting Shi  1, Hisakazu Iwama  2, Koji Fujita  1, Hideki Kobara  1, Noriko Nishiyama  1, Shintaro Fujihara  1, Yasuhiro Goda  1, Hirohito Yoneyama  1, Asahiro Morishita  1, Joji Tani  1, Mari Yamada  1, Mai Nakahara  1, Kei Takuma  1, Tsutomu Masaki  1

作者单位 +展开

作者单位

  • 1 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki 761-0793, Japan.
  • 2 Life Science Research Center, Kagawa University, 1750-1 Ikenobe, Miki 761-0793, Japan.
  • DOI: 10.3390/ijms222313071 PMID: 34884875

    摘要 Ai翻译

    Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during HCC treatment. Lenvatinib has been approved as a first-line systemic treatment for advanced HCC and is the first agent to achieve non-inferiority against sorafenib. Therefore, in the present study... ...点击完成人机验证后继续浏览
    Copyright © International journal of molecular sciences. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:International journal of molecular sciences

    缩写:INT J MOL SCI

    ISSN:1661-6596

    e-ISSN:1422-0067

    IF/分区:4.9/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells